Strong Tower Advisory Services Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Strong Tower Advisory Services raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,991 shares of the company’s stock after acquiring an additional 1,467 shares during the period. Strong Tower Advisory Services’ holdings in Novo Nordisk A/S were worth $2,150,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Carolina Wealth Advisors LLC acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $48,000. Finally, M&R Capital Management Inc. grew its position in shares of Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Monday. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The stock has a fifty day moving average price of $97.76 and a 200 day moving average price of $117.05. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.